BEATRICE PEKU: Open Payments
NPI 1285043851 · CHESHIRE, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,451 in 24 payments from 11 companies in 2025. Trend: 2023 $2,055 · 2024 $1,137 · 2025 $2,451
Food & beverage: $2,451
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $526 |
| Axsome Therapeutics, Inc. | 4 | $483 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $269 |
| Otsuka America Pharmaceutical, Inc. | 2 | $246 |
| Alkermes, Inc. | 2 | $243 |
| Luye Pharma (USA) Ltd. | 2 | $139 |
| ABBVIE INC. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Indivior Inc. | 1 | $122 |
| Neurocrine BioSciences, Inc. | 1 | $111 |
Products named: Auvelity, CAPLYTA, AUSTEDO XR, UZEDY, ERZOFRI EXTENDED-RELEASE, REXULTI, VRAYLAR, COBENFY.
Industry payments across CT — which companies pay providers there.
